Pharmaceutical Preparations · NV · CIK 1509261
Rezolute, Inc. develops treatments for hypoglycemia caused by hyperinsulinism
Comparable business profile · signals at a glance
In the 90 days to Mar 30, 2026: 1 insider bought $29K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Evans DaronCFO | Buy | 10,000 | $2.85 | $29K |
| Dec 16, 2025 | Roberts Brian KennethChief Medical Officer | Buy | 28,000 | $1.70 | $48K |
| Dec 16, 2025 | Hogenhuis WladimirDirector | Buy | 5,650 | $1.69 | $10K |
| Dec 15, 2025 | Evans DaronCFO | Buy | 40,000 | $1.77 | $71K |
| Dec 15, 2025 | Elam Nevan CCEO | Buy | 32,000 | $1.59 | $51K |
| Dec 15, 2025 | Karnawat Sunil RatilalChief Commercial Officer | Buy | 12,000 | $1.62 | $19K |
| Dec 15, 2025 | Evans DaronCFO | Buy | 2,500 | $1.79 | $4K |
| Dec 15, 2025 | Karnawat Sunil RatilalChief Commercial Officer | Buy | 100 | $1.60 | $160 |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.